• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.

作者信息

Calvo Charlotte, Cabannes-Hamy Aurélie, Adjaoud Dalila, Bruno Bénédicte, Blanc Laurence, Boissel Nicolas, Tabone Marie-Dominique, Willson-Plat Geneviève, Villemonteix Juliette, Baruchel André, Brethon Benoit

机构信息

Pediatric Hematology and Immunology Department, Robert Debré University Hospital (APHP and Université de Paris), Paris, France.

Adolescent and Young Adult Hematology Unit, Saint-Louis Hospital (APHP and Université de Paris), Paris, France.

出版信息

Br J Haematol. 2020 Jul;190(1):e53-e56. doi: 10.1111/bjh.16732. Epub 2020 May 18.

DOI:10.1111/bjh.16732
PMID:32424837
Abstract
摘要

相似文献

1
Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.因诺妥珠单抗奥佐米星在法国复发或难治性CD22阳性B细胞急性淋巴细胞白血病儿科患者中的同情用药。
Br J Haematol. 2020 Jul;190(1):e53-e56. doi: 10.1111/bjh.16732. Epub 2020 May 18.
2
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.INO-VATE 试验中的伊妥珠单抗奥唑米星治疗复发/难治性急性淋巴细胞白血病：根据基线 CD22 评估 CD22 药效动力学、疗效和安全性
Clin Cancer Res. 2021 May 15;27(10):2742-2754. doi: 10.1158/1078-0432.CCR-20-2399. Epub 2021 Feb 18.
3
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.使用奥英妥珠单抗治疗的复发或难治性急性淋巴细胞白血病患者的周期数对治疗结果的影响
Br J Haematol. 2020 Nov;191(3):e77-e81. doi: 10.1111/bjh.17029. Epub 2020 Aug 17.
4
Inotuzumab Ozogamicin: First Pediatric Approval.依妥珠单抗奥佐米星：首款获儿科批准的药物。
Paediatr Drugs. 2024 Jul;26(4):459-467. doi: 10.1007/s40272-024-00634-w. Epub 2024 May 23.
5
Loss of CD22 expression and expansion of a CD22 subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.在接受 Inotuzumab-Ozogamicin 治疗后，复发/难治性 B 淋巴细胞白血病成人患者中 CD22 表达缺失和 CD22 亚群扩增。
Ann Hematol. 2021 Nov;100(11):2727-2732. doi: 10.1007/s00277-021-04601-0. Epub 2021 Jul 31.
6
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.依妥珠单抗：从临床前研发到在 B 细胞急性淋巴细胞白血病中的成功。
Blood Adv. 2019 Jan 8;3(1):96-104. doi: 10.1182/bloodadvances.2018026211.
7
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.在 III 期 INO-VATE 试验中，采用奥加米星治疗复发/难治性急性淋巴细胞白血病患者的微小残留病状态的影响。
Leuk Res. 2020 Jan;88:106283. doi: 10.1016/j.leukres.2019.106283. Epub 2019 Nov 25.
8
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.英妥珠单抗奥佐米星联合低强度化疗（mini-HCVD）与或不联合blinatumomab 对比标准强化化疗（HCVAD）作为费城染色体阴性急性淋巴细胞白血病老年患者一线治疗：倾向评分分析。
Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.
9
Antibody based therapy in relapsed acute lymphoblastic leukemia.抗体药物治疗复发急性淋巴细胞白血病。
Best Pract Res Clin Haematol. 2020 Dec;33(4):101225. doi: 10.1016/j.beha.2020.101225. Epub 2020 Nov 18.
10
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).一项评估奥加米妥珠单抗治疗儿童复发/难治性急性淋巴细胞白血病的 1 期临床研究（ITCC-059 研究）。
Blood. 2021 Mar 25;137(12):1582-1590. doi: 10.1182/blood.2020007848.

引用本文的文献

1
Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP-ALL After Tisagenlecleucel: A Case Series.因诺妥珠单抗奥唑米星作为替沙格韦单抗治疗后复发的儿童BCP-ALL患者干细胞移植的桥梁：病例系列
Cancer Rep (Hoboken). 2025 Mar;8(3):e70177. doi: 10.1002/cnr2.70177.
2
Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia.奥英妥珠单抗作为复发/难治性急性淋巴细胞白血病儿童的四线挽救疗法实现完全缓解
Hematol Rep. 2024 Sep 27;16(4):579-584. doi: 10.3390/hematolrep16040056.
3
Inotuzumab Ozogamicin: First Pediatric Approval.
依妥珠单抗奥佐米星：首款获儿科批准的药物。
Paediatr Drugs. 2024 Jul;26(4):459-467. doi: 10.1007/s40272-024-00634-w. Epub 2024 May 23.
4
Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute Lymphoblastic Leukemia.利用免疫系统：小儿急性淋巴细胞白血病的当前及新兴免疫治疗策略
Biomedicines. 2023 Jul 3;11(7):1886. doi: 10.3390/biomedicines11071886.
5
Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.儿科急性淋巴细胞白血病的新兴疗法-从通路到靶点。
Int J Mol Sci. 2023 Feb 28;24(5):4661. doi: 10.3390/ijms24054661.
6
Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas.白血病和淋巴瘤患儿靶向治疗的感染并发症
Cancers (Basel). 2022 Oct 14;14(20):5022. doi: 10.3390/cancers14205022.
7
Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era.小儿复发性或难治性急性B细胞系淋巴细胞白血病的新型治疗方法：精准医学时代
Front Pediatr. 2022 Jun 23;10:923419. doi: 10.3389/fped.2022.923419. eCollection 2022.
8
Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia.儿童急性淋巴细胞白血病治疗方案的最新进展
Cancers (Basel). 2022 Apr 16;14(8):2021. doi: 10.3390/cancers14082021.
9
Haematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukaemia: Special Considerations and Challenges.青少年和青年急性淋巴细胞白血病患者的造血干细胞移植：特殊考量与挑战
Front Pediatr. 2022 Jan 11;9:796426. doi: 10.3389/fped.2021.796426. eCollection 2021.
10
Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias.小儿急性白血病现代治疗方法的见解
Cells. 2022 Jan 2;11(1):139. doi: 10.3390/cells11010139.